Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
16.70
+1.77 (11.86%)
At close: Apr 1, 2026, 4:00 PM EDT
17.03
+0.33 (1.98%)
After-hours: Apr 1, 2026, 7:42 PM EDT
Company Description
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases.
The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.
Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Avalo Therapeutics, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Oct 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Garry Neil |
Contact Details
Address: 540 Gaither Road, Suite 400 Rockville, Maryland 20850 United States | |
| Phone | 410 522 8707 |
| Website | avalotx.com |
Stock Details
| Ticker Symbol | AVTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534120 |
| CUSIP Number | 05338F108 |
| ISIN Number | US05338F3064 |
| Employer ID | 45-0705648 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Garry A. Neil M.D. | President, Chief Executive Officer and Director |
| Dr. Mittie Doyle FACR, M.D. | Chief Medical Officer |
| Taylor Boyd | Chief Business Officer |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board |
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board |
| Paul C. Varki J.D., M.P.H | Chief Legal Officer |
| Ashley Ivanowicz | Senior Vice President of Human Resources |
| Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC and Technical Operations |
| Jennifer Riley | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2026 | 144 | Filing |
| Apr 1, 2026 | SCHEDULE 13G | Filing |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 23, 2026 | 10-K | Annual Report |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 16, 2026 | 144 | Filing |
| Mar 6, 2026 | SCHEDULE 13G | Filing |
| Feb 24, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |